The Motley Fool

Leading brokers name 3 ASX shares to buy today

Once again, brokers across Australia have been working hard on their financial models and adjusting their recommendations accordingly.

Three shares that have come out of this favourably are listed below. Here’s why they have been given buy ratings this week:

Galaxy Resources Limited (ASX: GXY)

According to a note out of Credit Suisse, its analysts have upgraded this lithium miner’s shares to an outperform rating with a $3.15 price target. Although the broker acknowledges that Galaxy’s December quarter was below its expectations and that 2019 lithium prices have continued to slide, its analysts still see a lot of value in Galaxy’s shares at the current level. While I do agree with Credit Suisse, I wouldn’t be a buyer until lithium prices have bottomed.

ResMed Inc. (ASX: RMD)

Analysts at Morgans have retained their add rating but cut the price target on the sleep treatment-focused medical device company’s shares to $16.31 following its second quarter update. According to the note, the broker believes that the selloff of ResMed’s shares has been overdone and that they are very much in the buy zone now. Morgans continues to believe that the company is well-positioned for growth. I agree with the broker on ResMed and think the selloff has created a buying opportunity.

Seven Group Holdings Ltd (ASX: SVW)

A note out of Goldman Sachs reveals that its analysts have retained their buy rating and $22.10 price target on this diversified investment company’s shares following US giant Caterpillar’s results release. Although the latter’s results thoroughly underwhelmed overnight, Goldman remains positive on Seven’s WesTrac business. It believes that we are in the early stages of a multi-year mining investment cycle, putting Seven in a great position to profit. While it is a little soon for me to invest, if Goldman is correct then I think Seven Group could end up being a great investment.

Analyst Names 3 ASX shares to buy in February

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2019."

Each one pays a fully franked dividend. The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro owns shares of Galaxy Resources Limited. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

One ASX Stock For An Estimated $US22 Billion Marijuana Market

A little-known ASX company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

And make no mistake – it is coming. To the tune of an estimated $US22 billion.

Cannabis legalisation is sweeping over North America, and full legalisation arrived in Canada in October 2018.

Here’s the best part: we think there’s one ASX stock that’s uniquely positioned to profit immensely from this explosive new industry… taking savvy investors along for what could be one heck of a ride.

AND, this is the first time The Motley Fool Australia has EVER put a BUY recommendation on a marijuana stock.

Simply click below to learn more on how you can profit from the coming cannabis boom.

Click here to find out more